The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more ...

Roche’s Evrysdi tablet receives US FDA approval for the treatment of spinal muscular atrophy: Basel Friday, February 14, 2025, 13:00 Hrs [IST] Roche, announced that the US Food ...

Roche has announced that a tablet formulation of its spinal muscular atrophy (SMA) treatment Evrysdi (risdiplam) has been ...

Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments ...

Basel: Roche, announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an ...

Market OverviewThe Orphan Drugs Market is a specialized sector within the pharmaceutical industry that focuses on the ...

Lakeside Holding Limited ("Lakeside" or the "Company") , a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market operating through two specialized ...

Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...

The U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of Evrysdi (risdiplam), an approved oral ...

Sumitomo Mitsui Trust Group Inc. lessened its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 20.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor ...